A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs IDH 305 (Primary)
- Indications Acute myeloid leukaemia; Cancer; Glioma; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
- 01 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 2 Feb 2018.
- 06 Dec 2016 Results of preliminary analysis (n=81) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 29 Nov 2016 Status changed from recruiting to suspended.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History